Table S2 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways | Synapse
September 16, 2024
Table S2 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
Key Points
Key points are not available for this paper at this time.
Abstract
Individual patients with H3K27M-mutant DMG treated with ONC201.